Tyrosine kinase inhibitors as next generation oncological therapeutics: Current strategies, limitations and future perspectives
Tài liệu tham khảo
Nurgali, 2018, Adverse effects of cancer chemotherapy: anything new to improve tolerance and reduce sequelae?, Front Pharmacol, 9, 254, 10.3389/fphar.2018.00245
Manning, 2002, The protein kinase complement of the human genome, Science, 298, 1912, 10.1126/science.1075762
Carles, 2018, PKIDB: a curated, annotated and updated database of protein kinase inhibitors in clinical trials, Molecules, 23, 908, 10.3390/molecules23040908
Broekman, 2011, Tyrosine kinase inhibitors: multi-targeted or single-targeted?, World J Clin Oncol, 2, 80, 10.5306/wjco.v2.i2.80
Pawson, 2002, Regulation and targets of receptor tyrosine kinases, Eur J Cancer, 38, S3, 10.1016/S0959-8049(02)80597-4
FDA, 2019
FDA, 2019
FDA, 2019
FDA, 2021
FDA, 2019
FDA, 2018
FDA, 2016
FDA, 2004
FDA, 2018
FDA, 2020
FDA, 2020
FDA, 2020
FDA, 2021
FDA, 2021
FDA, 2021
FDA, 2021
FDA, 2020
FDA, 2020
FDA, 2021
FDA, 2020
FDA, 2020
FDA, 2020
FDA, 2020
FDA, 2019
FDA, 2018
FDA, 2020
FDA, 2021
FDA, 2021
FDA, 2020
FDA, 2021
FDA, 2020
FDA, 2020
FDA, 2021
FDA, 2019
FDA, 2019
FDA, 2020
FDA, 2021
FDA, 2018
FDA, 2019
FDA, 2018
FDA, 2021
FDA, 2020
FDA, 2020
FDA, 2020
FDA, 2021
FDA, 2018
FDA, 2018
FDA, 2020
FDA, 2021
FDA, 2020
Bixby, 2009, Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukaemia and recent therapeutic strategies to overcome resistance, Hematology Am Soc Hematol Educ Program, 2009, 461, 10.1182/asheducation-2009.1.461
Ozvegy-Laczka, 2005, Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters, Drug Resist Updat, 8, 15, 10.1016/j.drup.2005.02.002
Thanki, 2013, Oral delivery of anticancer drugs: challenges and opportunities, J Control Release, 170, 15, 10.1016/j.jconrel.2013.04.020
Ambudkar, 1999, Biochemical, cellular, and pharmacological aspects of the multidrug transporter, Annu Rev Pharmacol Toxicol, 39, 361, 10.1146/annurev.pharmtox.39.1.361
Singh, 2002, Drug delivery-oral route, 1242
Gonzalez, 2006, Drug metabolism, 71
Stuhlmiller, 2015, Inhibition of lapatinib-induced kinome reprogramming in ERBB2-positive breast cancer by targeting BET family bromodomains, Cell Rep, 11, 390, 10.1016/j.celrep.2015.03.037
Qi, 2017, Co-delivery nanoparticles of anticancer drugs for improving chemotherapy efficacy, Drug Deliv, 24, 1909, 10.1080/10717544.2017.1410256
Robinson, 2000, The protein-tyrosine kinase family of the human genome, Oncogene, 19, 5548, 10.1038/sj.onc.1203957
Van der Geer, 1994, Receptor protein-tyrosine kinases and their signal transduction pathways, Annu Rev Cell Biol, 10, 251, 10.1146/annurev.cb.10.110194.001343
Linggi, 2006, ErbB receptors: new insights on mechanisms and biology, Trends Cell Biol, 16, 649, 10.1016/j.tcb.2006.10.008
Roskoski, 2014, The ErbB/HER family of protein-tyrosine kinases and cancer, Pharmacol Res, 79, 34, 10.1016/j.phrs.2013.11.002
Sasaki, 2013, The role of epidermal growth factor receptor in cancer metastasis and microenvironment, BioMed Res Int, 2013, 1, 10.1155/2013/546318
Wee, 2017, Epidermal growth factor receptor cell proliferation signaling pathways, Cancers, 9, 52, 10.3390/cancers9050052
Pines, 2010, Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy, FEBS Lett, 584, 2699, 10.1016/j.febslet.2010.04.019
Endres, 2014, Emerging concepts in the regulation of the EGF receptor and other receptor tyrosine kinases, Trends Biochem Sci, 39, 437, 10.1016/j.tibs.2014.08.001
Gan, 2013, The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered, FEBS J, 280, 5350, 10.1111/febs.12393
Mendelsohn, 2000, The EGF receptor family as targets for cancer therapy, Oncogene, 19, 6550, 10.1038/sj.onc.1204082
Vassilev, 2004, Therapeutic potential of inhibiting Bruton's tyrosine kinase (BTK), Curr Pharm Des, 10, 1757, 10.2174/1381612043384475
Liang, 2018, The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: a mini-review, Eur J Med Chem, 151, 315, 10.1016/j.ejmech.2018.03.062
Boyken, 2012, Rescue of the aggregation prone Itk Pleckstrin Homology domain by two mutations derived from the related kinases, Btk and Tec, Protein Sci, 21, 1288, 10.1002/pro.2114
Tao, 2012, B cell receptor (BCR) signal pathways confer microenvironment-mediated drug resistance and are promising therapeutic targets for B cell lymphomas, Blood, 120, 4918, 10.1182/blood.V120.21.4918.4918
Rankin, 2013, 3rd selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis, J Immunol, 191, 4540, 10.4049/jimmunol.1301553
Fremd, 2013, B cell-regulated immune responses in tumor models and cancer patients, Oncoimmunology, 2, e25443, 10.4161/onci.25443
An, 2010, BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome-positive chronic myeloid leukaemia: a review, Leuk Res, 34, 1255, 10.1016/j.leukres.2010.04.016
Rowley, 1973, Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining, Nature, 243, 290, 10.1038/243290a0
Kantarjian, 2007, Important therapeutic targets in chronic myelogenous leukaemia, Clin Cancer Res, 13, 1089, 10.1158/1078-0432.CCR-06-2147
Sawyers, 1997, Signal transduction pathways involved in BCR-ABL transformation, Baillieres Clin Haematol, 10, 223, 10.1016/S0950-3536(97)80004-2
Savage, 2002, Imatinib mesylate—a new oral targeted therapy, N Engl J Med, 346, 683, 10.1056/NEJMra013339
Holtz, 2002, Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukaemia through reversal of abnormally increased proliferation, Blood, 99, 3792, 10.1182/blood.V99.10.3792
Quintas-Cardama, 2007, Flying under the radar: the new wave of BCR-ABL inhibitors, Nat Rev Drug Discov, 6, 834, 10.1038/nrd2324
O’Hare, 2005, In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants, Cancer Res, 65, 4500, 10.1158/0008-5472.CAN-05-0259
Nilsson, 2006, Vascular endothelial growth factor (VEGF) pathway, J Thorac Oncol, 1, 768, 10.1016/S1556-0864(15)30404-4
Roskoski, 2016, Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases, Pharmacol Res, 111, 784, 10.1016/j.phrs.2016.07.038
Diaz, 2011, Lestaurtinib inhibition of the Jak/STAT signaling pathway in Hodgkin lymphoma inhibits proliferation and induces apoptosis, PLoS One, 6, e18856, 10.1371/journal.pone.0018856
Bechman, 2019, The new entries in the therapeutic armamentarium: the small molecule JAK inhibitors, Pharmacol Res, 147, 104392, 10.1016/j.phrs.2019.104392
Donahue, 2008, Evaluation of human brain tumor heterogeneity using multipleT1-based MRI signal weighting approaches, Magn Reson Med, 59, 336, 10.1002/mrm.21467
Agarwal, 2011, Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain, Expert Rev Mol Med, 13, e17, 10.1017/S1462399411001888
Zhou, 2018, Development of a nanoliposomal formulation of erlotinib for lung cancer and in vitro/in vivo antitumoral evaluation, Drug Des Dev Ther, 12, 1, 10.2147/DDDT.S146925
Herbst, 2004, Gefitinib—a novel targeted approach to treating cancer, Nat Rev Cancer, 4, 956, 10.1038/nrc1506
Wang, 2012, Nanoparticle delivery of cancer drugs, Annu Rev Med, 63, 185, 10.1146/annurev-med-040210-162544
Wang, 2019, Uniform carboxymethyl chitosan-enveloped Pluronic F68/poly(lactic-co-glycolic acid) nano-vehicles for facilitated oral delivery of gefitinib, a poorly soluble antitumor compound, Colloids Surf B, 177, 425, 10.1016/j.colsurfb.2019.02.028
Janjigian, 2014, Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations, Cancer Discov, 4, 1036, 10.1158/2159-8290.CD-14-0326
Helena, 2013, Afatinib—new therapy option for EGFR-mutant lung cancer, Nat Rev Clin Oncol, 10, 551, 10.1038/nrclinonc.2013.154
Yang, 2019, PLGA porous microspheres dry powders for co-delivery of afatinib-loaded solid lipid nanoparticles and paclitaxel: novel therapy for EGFR tyrosine kinase inhibitors resistant non-small cell lung cancer, Adv Healthc Mater, 8, e1900965, 10.1002/adhm.201900965
Lee, 2018, Mitochondria targeting and destabilizing hyaluronic acid derivative-based nanoparticles for the delivery of lapatinib to triple-negative breast cancer, Biomacromolecules, 20, 835, 10.1021/acs.biomac.8b01449
Ke, 2018, Transferrin receptor-targeted HMSN for sorafenib delivery in refractory differentiated thyroid cancer therapy, Int J Nanomedicine, 13, 8339, 10.2147/IJN.S187240
Iacobazzi, 2017, Targeting human liver cancer cells with lactobionic acid-G (4)-PAMAM-FITC sorafenib loaded dendrimers, Int J Pharm, 528, 485, 10.1016/j.ijpharm.2017.06.049
Shafie, 2019, Sorafenib-loaded PAMAM dendrimer attenuates liver fibrosis and its complications in bile-duct-ligated rats, Can J Physiol Pharmacol, 97, 691, 10.1139/cjpp-2019-0141
Zacchia, 2010, Genomic and proteomic approaches to renal cell carcinoma, J Nephrol, 24, 155, 10.5301/JN.2010.90
Keisner, 2011, The newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma, Drugs, 378, 1931
Deng, 2013, Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer, Xenobiotica, 43, 443, 10.3109/00498254.2012.734642
Cairns, 2006, Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment unique microenvironment of solid tumors, Mol Cancer Res, 4, 61, 10.1158/1541-7786.MCR-06-0002
Tailor, 2010, Effect of pazopanib on tumor microenvironment and liposome delivery, Mol Cancer Ther, 9, 1798, 10.1158/1535-7163.MCT-09-0856
Şanlıer, 2019, Development of ultrasound-triggered and magnetic-targeted nanobubble system for dual-drug delivery, J Pharm Sci, 108, 1272, 10.1016/j.xphs.2018.10.030
Khurana, 2014, Novel pentablock copolymer based nanoparticles containing pazopanib: a potential therapy for ocular neovascularization, Recent Pat Nanomed, 4, 57, 10.2174/1877912304999140930143244
Solimando, 2013, Drug monographs: bosutinib and regorafenib, Hosp Pharm, 48, 190, 10.1310/hpj4803-190
Zhou, 2020, Co-drug delivery of regorafenib and cisplatin with amphiphilic copolymer nanoparticles: enhanced in vivo antitumor cancer therapy in nursing care, Drug Deliver, 27, 1319, 10.1080/10717544.2020.1815897
Chow, 2007, Sunitinib: from rational design to clinical efficacy, J Clin Oncol, 25, 884, 10.1200/JCO.2006.06.3602
Faivre, 2007, Molecular basis for sunitinib efficacy and future clinical development, Nat Rev Drug Discov, 6, 734, 10.1038/nrd2380
Adams, 2007, Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors, Clin Ther, 29, 1338, 10.1016/j.clinthera.2007.07.022
Grünwald, 2007, Managing side effects of angiogenesis inhibitors in renal cell carcinoma, Oncol Res Treat, 30, 519, 10.1159/000107721
Hu, 2016, In vitro and in vivo evaluation of targeted sunitinib-loaded polymer microbubbles against proliferation of renal cell carcinoma, J Ultrasound Med, 35, 589, 10.7863/ultra.14.10038
Van Wamel, 2004, Micromanipulation of endothelial cells: ultrasound-microbubble-cell interaction, Ultrasound Med Biol, 30, 1255, 10.1016/j.ultrasmedbio.2004.07.015
Eisenbrey, 2009, Ultrasound-triggered cell death in vitro with doxorubicin loaded poly-lactic-acid contrast agents, Ultrasonics, 49, 628, 10.1016/j.ultras.2009.03.003
Shi, 2015, A combination of targeted sunitinib liposomes and targeted vinorelbine liposomes for treating invasive breast cancer, J Biomed Nanotechnol, 11, 1568, 10.1166/jbn.2015.2075
Hayes, 2014, Activation of platelet-derived growth factor receptor alpha contributes to liver fibrosis, PLoS One, 9, e92925, 10.1371/journal.pone.0092925
Wagner, 2013, Receptor tyrosine kinases fall into distinct classes based on their inferred signaling networks, Sci Signal, 6, ra58, 10.1126/scisignal.2003994
Weisberg, 2006, AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL, Br J Cancer, 94, 1765, 10.1038/sj.bjc.6603170
Zakkula, 2020, Preparation and optimization of nilotinib self-micro-emulsifying drug delivery systems to enhance oral bioavailability, Drug Dev Ind Pharm, 46, 498, 10.1080/03639045.2020.1730398
Lombardo, 2004, Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays, J Med Chem, 47, 6658, 10.1021/jm049486a
Zeng, 2018, Efficacy in treating lung metastasis of invasive breast cancer with functional vincristine plus dasatinib liposomes, Pharmacology, 101, 43, 10.1159/000480737
Lu, 2009, Breast cancer metastasis: challenges and opportunities, Cancer Res, 69, 4951, 10.1158/0008-5472.CAN-09-0099
Breccia, 2021, Asciminib: an investigational agent for the treatment of chronic myeloid leukaemia, Expert Opin Investig Drugs, 30, 803, 10.1080/13543784.2021.1941863
Paghdal, 2007, Sirolimus (rapamycin): from the soil of Easter Island to a bright future, J Am Acad Dermatol, 57, 1046, 10.1016/j.jaad.2007.05.021
Oshiro, 2004, Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function, Genes Cells, 9, 359, 10.1111/j.1356-9597.2004.00727.x
Valizadeh, 2015, Fusogenic liposomal formulation of sirolimus: improvement of drug anti-proliferative effect on human T cells, Drug Dev Ind Pharm, 41, 1558, 10.3109/03639045.2014.971032
Behrouz, 2016, Enhanced cytotoxicity to cancer cells by co-delivery and controlled release of paclitaxel-loaded sirolimus-conjugated albumin nanoparticles, Chem Biol Drug Des, 88, 230, 10.1111/cbdd.12750
Teachey, 2009, Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies, Br J Haematol, 145, 569, 10.1111/j.1365-2141.2009.07657.x
Ayoub, 2012, Advances in the management of metastatic breast cancer: options beyond first-line chemotherapy, Curr Oncol, 19, 91, 10.3747/co.19.1024
Gallardo, 2012, Increased signaling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas, Br J Cancer, 106, 1367, 10.1038/bjc.2012.85
Houdaihed, 2020, Dual-targeted delivery of nanoparticles encapsulating paclitaxel and everolimus: a novel strategy to overcome breast cancer receptor heterogeneity, Pharm Res, 37, 39, 10.1007/s11095-019-2684-6
Pal, 2019, Co-delivery of everolimus and vinorelbine via a tumor-targeted liposomal formulation inhibits tumor growth and metastasis in RCC, Int J Nanomedicine, 14, 5109, 10.2147/IJN.S204221
Honigberg, 2010, The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy, Proc Natl Acad Sci U S A, 107, 13075, 10.1073/pnas.1004594107
Kim, 2015, Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia, Drugs, 75, 769, 10.1007/s40265-015-0380-3
de Vries, 2016, Stable isotope-labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults, Br J Clin Pharmacol, 81, 235, 10.1111/bcp.12787
Zhao, 2020, Chitosan/sulfobutylether-β-cyclodextrin nanoparticles for ibrutinib delivery: a potential nanoformulation of novel kinase inhibitor, J Pharm Sci, 109, 1136, 10.1016/j.xphs.2019.10.007
Shinde, 2015, The contrasting recognition behavior of ß-cyclodextrin and its sulfobutylether derivative towards 4′,6-diamidino-2-phenylindole, Chemphyschem, 16, 3425, 10.1002/cphc.201500638
Shakeel, 2016, Bioavailability enhancement and pharmacokinetic profile of an anticancer drug ibrutinib by self-nano-emulsifying drug delivery system, J Pharm Pharmacol, 68, 772, 10.1111/jphp.12550
Han, 2018, Ruxolitinib synergistically enhances the antitumor activity of paclitaxel in human ovarian cancer, Oncotarget, 9, 24304, 10.18632/oncotarget.24368
Kiladjian, 2015, Ruxolitinib for the treatment of patients with polycythemia vera, Expert Rev Hematol, 8, 391, 10.1586/17474086.2015.1045869
Pardanani, 2011, JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations, Leukemia, 25, 218, 10.1038/leu.2010.269
Keohane, 2015, JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells, Br J Haematol, 171, 60, 10.1111/bjh.13519